We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Radioactive Carbon Incorporated in Urea for H. Pylori Test

By LabMedica International staff writers
Posted on 26 Nov 2008
The noninvasive test method used clinically for the diagnosis of Helicobacter pylori infection and post-eradication follow-up is the urea breath test (UBT). More...
A probe for the bacteria has been developed by incorporating a radioactive isotope of carbon into the urea used for the test.

H. pylori produce an enzyme, urease, which catalyzes the hydrolysis of the urea molecule into ammonium and carbon dioxide. The urea contains one carbon atom that is replaced by the radioactive carbon isotope. The probe, developed by Stat Diagnostics Services (Mumbai, India), is called the Heliprobe instrument.

A Helicap (hard urea 14C) is ingested with 50 ml of water. When H. pylori are present in the stomach, urease metabolizes the C-urea releasing carbon dioxide containing the C-labeled atoms. The carbon dioxide passes through the mucosa into the blood stream and it is transported to the lungs where it is exhaled. The amount of CO2 produced in the stomach can be measured with the Heliprobe instrument.

If the patient is not infected, no metabolisation of urea will occur and therefore no CO2 is detected--the unmetabolised C urea will be excreted in the urine. If the Heliprobe system detects CO2, this is diagnostic evidence of an ongoing infection with H. pylori.

Related Links:
Stat Diagnostics Services



Gold Member
Respiratory Syncytial Virus Test
OSOM® RSV Test
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gold Member
Collection and Transport System
PurSafe Plus®
Gold Member
Hematology Analyzer
Medonic M32B
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The TmS computational biomarker analyzes tumor gene expression and microenvironment data to guide treatment decisions (Photo courtesy of MD Anderson Cancer Center)

New Biomarker Predicts Chemotherapy Response in Triple-Negative Breast Cancer

Triple-negative breast cancer is an aggressive form of breast cancer in which patients often show widely varying responses to chemotherapy. Predicting who will benefit from treatment remains challenging,... Read more

Industry

view channel
Image: The initiative aims to speed next-generation diagnostic development during early pathogen emergence (photo courtesy of 123RF)

Cepheid Joins CDC Initiative to Strengthen U.S. Pandemic Testing Preparednesss

Cepheid (Sunnyvale, CA, USA) has been selected by the U.S. Centers for Disease Control and Prevention (CDC) as one of four national collaborators in a federal initiative to speed rapid diagnostic technologies... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.